EpizymeInc.
Mosunetuzumab(Epizyme, Inc.)은 FRα 표적 항체로, Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA). Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 87.5% (ClinicalTrials.gov NCT03677141). 차별점: novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas.
FRα
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Recruiting
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
vedotin in patients with relapsed/refractory la
lentiviral short hairpin RNA
humanized NOD/Shi-scid, IL-2Rγnull (huNOG) mice were used for an in vivo study
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA)
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were more frequently reported i
CD20 RO% was high
bypassing MHC presentation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
EpizymeInc.
Mosunetuzumab(Epizyme, Inc.)은 FRα 표적 항체로, Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA). Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 87.5% (ClinicalTrials.gov NCT03677141). 차별점: novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas.
FRα
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Recruiting
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
vedotin in patients with relapsed/refractory la
lentiviral short hairpin RNA
humanized NOD/Shi-scid, IL-2Rγnull (huNOG) mice were used for an in vivo study
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA)
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were more frequently reported i
CD20 RO% was high
bypassing MHC presentation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.